Drugs / Tumor Infiltrating Lymphocytes (TILs)
last change Aug 2020 re-read 2 minutes ago

Tumor Infiltrating Lymphocytes (TILs)

Cell therapy

Developed for
cutaneous melanoma
Investigated by
Bristol-Myers Squibb · H. Lee Moffitt Cancer Center and Research Institute · Iovance Biotherapeutics, Inc. · Prometheus Inc.

Trials 1 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT02652455 Mar 2016 → Aug 2020 cutaneous melanoma H. Lee Moffitt Cancer Center and Research Institute Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Tumor Infiltrating Lymphocytes (TILs) Tumor Infiltrating Lymphocytes (TILs)NCT02652455
Modality Cell therapy “Adoptive Cell TherapyNCT02652455
Route Intravenous “IV infusion of the TIL cells.” NCT02652455